John N. Allan, MD, discusses a pooled analysis of 4 clinical trials with 4-year follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia and TP53 aberration deletion 17p or a TP53 mutation.
John N. Allan, MD
Advertisement
Articles by John N. Allan, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Fast Track Designation to VS-7375 for KRAS G12D–Mutated NSCLC
2
ASCO 2026 GI Cancer Highlights: Beyond the LBAs
3
FDA Grants Fast Track Designation to TER-2013 for Advanced Breast Cancer
4
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
5